https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2013-11-25 13:54:072016-11-25 13:59:422013 ASH: Phase I/II Open-label study of AT7519 alone and in combo with bortezomib in pts with MM
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2011-11-25 13:59:542016-11-25 14:05:412011 EORTC: Phase 1 Study of AT7519M Short Infusion Twice Weekly
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2009-11-25 14:01:412016-11-25 14:09:472009 AACR: ID of Predicted Biologically Effective Dose of AT7519 in Phase 1 Study
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2008-08-25 14:10:082016-11-25 14:10:362008_A Dose Escalation, PK and PD Study of AT7519 in Patients with Refractory Solid Tumors
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2008-05-25 14:10:412016-11-25 14:11:072008 ASH_AT7519 is Active in CLL Patient Samples Independent of Stage
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2007-07-25 14:11:472016-11-25 14:12:322007 ASH_AT7519 is Active in Leukemia Models and Primary CLL Patient Samples
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2007-04-25 14:12:422016-11-25 14:13:062007_Comparison of AT7519 in Solid Tumor and Hematological Cell Lines
